Barclays’s Akebia Therapeutics AKBA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $198K | Sell |
142,192
-781,315
| -85% | -$1.07M | ﹤0.01% | 3688 |
|
|
2025
Q4 | $1.49M | Sell |
923,507
-256,726
| -22% | -$538K | ﹤0.01% | 3149 |
|
|
2025
Q3 | $3.22M | Buy |
1,180,233
+195,721
| +20% | +$651K | ﹤0.01% | 2511 |
|
|
2025
Q2 | $3.58M | Buy |
984,512
+676,377
| +220% | +$1.86M | ﹤0.01% | 2383 |
|
|
2025
Q1 | $592K | Sell |
308,135
-67,360
| -18% | -$137K | ﹤0.01% | 3420 |
|
|
2024
Q4 | $713K | Buy |
375,495
+102,410
| +38% | +$178K | ﹤0.01% | 3601 |
|
|
2024
Q3 | $360K | Buy |
273,085
+200,482
| +276% | +$268K | ﹤0.01% | 3973 |
|
|
2024
Q2 | $74.1K | Sell |
72,603
-137,397
| -65% | -$170K | ﹤0.01% | 4047 |
|
|
2024
Q1 | $384K | Buy |
+210,000
| New | +$336K | ﹤0.01% | 3752 |
|
|
2022
Q2 | – | Sell |
-84,146
| Closed | -$61K | – | 4997 |
|
|
2022
Q1 | $61K | Sell |
84,146
-200,624
| -70% | -$429K | ﹤0.01% | 4028 |
|
|
2021
Q4 | $643K | Buy |
284,770
+96,413
| +51% | +$263K | ﹤0.01% | 3084 |
|
|
2021
Q3 | $542K | Buy |
188,357
+19,081
| +11% | +$54.5K | ﹤0.01% | 3147 |
|
|
2021
Q2 | $642K | Sell |
169,276
-67,942
| -29% | -$229K | ﹤0.01% | 2927 |
|
|
2021
Q1 | $804K | Buy |
237,218
+73,426
| +45% | +$264K | ﹤0.01% | 2903 |
|
|
2020
Q4 | $458K | Sell |
163,792
-20,701
| -11% | -$60.4K | ﹤0.01% | 3289 |
|
|
2020
Q3 | $463K | Buy |
184,493
+49,439
| +37% | +$434K | ﹤0.01% | 3283 |
|
|
2020
Q2 | $1.83M | Buy |
135,054
+1,297
| +1% | +$13.4K | ﹤0.01% | 2206 |
|
|
2020
Q1 | $1.01M | Sell |
133,757
-37,133
| -22% | -$289K | ﹤0.01% | 2930 |
|
|
2019
Q4 | $1.08M | Buy |
170,890
+51,902
| +44% | +$247K | ﹤0.01% | 3603 |
|
|
2019
Q3 | $467K | Sell |
118,988
-10,615
| -8% | -$45.5K | ﹤0.01% | 4295 |
|
|
2019
Q2 | $628K | Buy |
129,603
+20,912
| +19% | +$119K | ﹤0.01% | 4123 |
|
|
2019
Q1 | $891K | Buy |
108,691
+106,653
| +5,233% | +$732K | ﹤0.01% | 3527 |
|
|
2018
Q4 | $11K | Sell |
2,038
-93,007
| -98% | -$728K | ﹤0.01% | 6124 |
|
|
2018
Q3 | $839K | Buy |
95,045
+80,240
| +542% | +$718K | ﹤0.01% | 3803 |
|
|
2018
Q2 | $148K | Sell |
14,805
-16,340
| -52% | -$164K | ﹤0.01% | 4978 |
|
|
2018
Q1 | $296K | Buy |
31,145
+13,161
| +73% | +$184K | ﹤0.01% | 4466 |
|
|
2017
Q4 | $268K | Buy |
17,984
+16,416
| +1,047% | +$272K | ﹤0.01% | 4434 |
|
|
2017
Q3 | $30K | Sell |
1,568
-12,330
| -89% | -$190K | ﹤0.01% | 5606 |
|
|
2017
Q2 | $199K | Buy |
13,898
+13,020
| +1,483% | +$165K | ﹤0.01% | 4354 |
|
|
2017
Q1 | $9K | Sell |
878
-3,174
| -78% | -$31K | ﹤0.01% | 6098 |
|
|
2016
Q4 | $43K | Buy |
4,052
+3,704
| +1,064% | +$31.9K | ﹤0.01% | 5251 |
|
|
2016
Q3 | $3K | Sell |
348
-145
| -29% | -$1.23K | ﹤0.01% | 6116 |
|
|
2016
Q2 | $4K | Buy |
493
+300
| +155% | +$2.62K | ﹤0.01% | 5774 |
|
|
2016
Q1 | $2K | Sell |
193
-266
| -58% | -$2.16K | ﹤0.01% | 5848 |
|
|
2015
Q4 | $6K | Sell |
459
-7,918
| -95% | -$80.8K | ﹤0.01% | 5515 |
|
|
2015
Q3 | $75K | Buy |
8,377
+7,854
| +1,502% | +$72.1K | ﹤0.01% | 4788 |
|
|
2015
Q2 | $6K | Buy |
523
+49
| +10% | +$418 | ﹤0.01% | 6330 |
|
|
2015
Q1 | $5K | Buy |
474
+29
| +7% | +$309 | ﹤0.01% | 6544 |
|
|
2014
Q4 | $4K | Buy |
445
+364
| +449% | +$5.22K | ﹤0.01% | 7004 |
|
|
2014
Q3 | $2K | Sell |
81
-2,400
| -97% | -$55.1K | ﹤0.01% | 7383 |
|
|
2014
Q2 | $67K | Buy |
+2,481
| New | +$59.7K | ﹤0.01% | 5741 |
|
Other funds holding AKBA
VCM
VPM
Barclays's AKBA Position: Q1 2026 in Review
Barclays reduced its Akebia Therapeutics (AKBA) stake by 85% in Q1 2026, selling an estimated $1.07M and leaving 142,192 shares worth $198K. The position accounts for ﹤0.01% of the portfolio, ranked #3688.
Barclays first reported a position in AKBA in Q2 2014 and has held it in 41 quarters since. The position peaked at $3.58M in Q2 2025. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.
- Barclays held 142,192 shares of Akebia Therapeutics worth $198K as of Q1 2026.
- Barclays sold 781,315 Akebia Therapeutics shares in Q1 2026, an estimated $1.07M.
- Akebia Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3688 holding.
- Barclays first reported a position in Akebia Therapeutics in Q2 2014 and has held it in 41 quarters since.
- Barclays's Akebia Therapeutics position peaked at $3.58M in Q2 2025.
- 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.